Halozyme Therapeutics, Inc. reiterating earnings guidance for the year 2022. For the year, the company expects net revenue to be in the range of $530 million to $560 million, GAAP operating income to be in the range of $350 million to $380 million, GAAP net income to be in the range of $270 million to $295 million and GAAP diluted EPS to be in the range of $1.90 to $2.05.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.3 USD | +3.15% | +0.46% | +6.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.33% | 4.84B | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022